Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2074034 | 1.00 | TP53 (0.35) | TP53KDM4EGAA | |
| SCHEMBL3844434 | 0.82 | KDM4E (0.35) | KDM4EGAA | |
| SCHEMBL9434415 | 0.82 | KDM4E (0.35) | KDM4EGAA | |
| SCHEMBL5601168 | 0.79 | KCNH2 (0.34) | KDM4E | |
| SCHEMBL5600229 | 0.77 | KCNH2 (0.41) | — | |
| SCHEMBL908059 | 0.76 | — | — | |
| SCHEMBL3830854 | 0.76 | TSHR (0.35) | — | |
| SCHEMBL6244276 | 0.76 | GABRA1 (0.33) | — | |
| SCHEMBL5110825 | 0.76 | ALDH1A1 (0.41) | KDM4E | |
| SCHEMBL5600616 | 0.76 | KCNH2 (0.44) | TP53KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230265103-A1 | NOVEL INHIBITORS OF PIKFYVE AND METHODS USING SAME | TME THERAPEUTICS LLC | 2023-08-24 | — | — | US | claimed |
| US-7276567-B2 | Heterocyclic substituted metallocene compounds for olefin polymerization | EXXONMOBIL CHEMICAL PATENTS INC. (US) | 2007-10-02 | — | — | US | claimed |
| US-20050261449-A1 | Heterocyclic substituted metallocene compounds for olefin polymerization | EXXONMOBIL CHEMICAL PATENT INC. | 2005-11-24 | — | — | US | claimed |
| EP-4383988-A1 | ORGANIC LIGHT EMITTING DIODE, DEVICE COMPRISING THE SAME AND COMPOUND | Novaled GmbH (DE) | 2024-06-12 | — | — | EP | disclosed |
| US-20230270004-A1 | Organic Light Emitting Diode and Device Comprising the Same | NOVALED GMBH (DE) | 2023-08-24 | — | — | US | disclosed |
| US-20230265103-A1 | NOVEL INHIBITORS OF PIKFYVE AND METHODS USING SAME | TME THERAPEUTICS LLC | 2023-08-24 | — | — | US | disclosed |
| US-20220194907-A1 | PROCESS FOR THE PREPARATION OF MICROBIOCIDAL OXADIAZOLE DERIVATIVES | SYNGENTA CROP PROTECTION AG (CH) | 2022-06-23 | — | — | US | disclosed |
| US-11259524-B2 | Microbiocidal oxadiazole derivatives | SYNGENTA PARTICIPATIONS AG (CH) | 2022-03-01 | — | — | US | disclosed |
| US-20210037826-A1 | MICROBIOCIDAL OXADIAZOLE DERIVATIVES | SYNGENTA PARTICIPATIONS AG (CH) | 2021-02-11 | — | — | US | disclosed |
| US-10798941-B2 | Microbiocidal oxadiazole derivatives | SYNGENTA PARTICIPATIONS AG (CH) | 2020-10-13 | — | — | US | disclosed |
| US-20190297892-A1 | MICROBIOCIDAL OXADIAZOLE DERIVATIVES | SYNGENTA PARTICIPATIONS AG (CH) | 2019-10-03 | — | — | US | disclosed |
| WO-2006061638-A2 | HETEROCYCLE DERIVATIVES AS HISTONE DEACETYLASE (HDAC) INHIBITORS | ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P ANGELETTI SPA (IT) | 2006-06-15 | — | — | WO | disclosed |
| US-20050261449-A1 | Heterocyclic substituted metallocene compounds for olefin polymerization | EXXONMOBIL CHEMICAL PATENT INC. | 2005-11-24 | — | — | US | disclosed |
| WO-2005105864-A1 | HETEROCYCLIC SUBSTITUTED METALLOCENE COMPOUNDS FOR OLEFIN POLYMERIZATION | EXXONMOBIL CHEMICAL PATENTS INC. (US) | 2005-11-10 | — | — | WO | disclosed |
| US-20040254198-A1 | Thienopyrimidinediones and their use in the modulation of autoimmune disease | ASTRAZENECA AB (SE) | 2004-12-16 | — | — | US | disclosed |
| US-20040171623-A1 | Chemical compounds | ASTRAZENECA AB (SE) | 2004-09-02 | — | — | US | disclosed |
| EP-1414825-A1 | THIENOPYRIMIDINEDIONES AND THEIR USE IN THE MODULATION OF AUTOIMMUNE DISEASE | AstraZeneca AB (SE) | 2004-05-06 | — | — | EP | disclosed |
| EP-1412362-A1 | CHEMICAL COMPOUNDS | Astrazeneca AB (SE) | 2004-04-28 | — | — | EP | disclosed |
| WO-2003011868-A1 | THIENOPYRIMIDINEDIONES AND THEIR USE IN THE MODULATION OF AUTOIMMUNE DISEASE | ASTRAZENECA AB (SE) | 2003-02-13 | — | — | WO | disclosed |
| WO-2003008422-A1 | CHEMICAL COMPOUNDS | ASTRAZENECA AB (SE) | 2003-01-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230265103-A1 | NOVEL INHIBITORS OF PIKFYVE AND METHODS USING SAME | PIKFYVE, PIK3CD, PIK3R5 | TP53 648/4885KDM4E 1554/4885GAA 2382/4885 |
| US-20210037826-A1 | MICROBIOCIDAL OXADIAZOLE DERIVATIVES | PRF1, NOX1, ARG1 | TP53 2838/4885KDM4E 2601/4885GAA 1460/4885 |
| US-10798941-B2 | Microbiocidal oxadiazole derivatives | PRF1, NOX1, ARG1 | TP53 2660/4885KDM4E 2627/4885GAA 1425/4885 |
| US-20190297892-A1 | MICROBIOCIDAL OXADIAZOLE DERIVATIVES | PRF1, NOX1, ARG1 | TP53 2660/4885KDM4E 2627/4885GAA 1425/4885 |
| US-20040171623-A1 | Chemical compounds | CBR1, SETDB1, CBR3 | TP53 3432/4885KDM4E 181/4885GAA 2477/4885 |
| US-20040254198-A1 | Thienopyrimidinediones and their use in the modulation of autoimmune disease | TPMT, CBR1, CYP2D6 | TP53 4248/4885KDM4E 1355/4885GAA 4481/4885 |
| US-11259524-B2 | Microbiocidal oxadiazole derivatives | PRF1, NOX1, ARG1 | TP53 2838/4885KDM4E 2601/4885GAA 1460/4885 |
| US-20220194907-A1 | PROCESS FOR THE PREPARATION OF MICROBIOCIDAL OXADIAZOLE DERIVATIVES | CYP51A1, MPO, NOX5 | TP53 4335/4885KDM4E 2124/4885GAA 482/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.